BCYC · Bicycle Therapeutics PLC · Documents

Apr 15

Proxy statement DEF 14A Meeting May 16, 2024

Proxy statement

Apr 15

Annual report to holders ARS

Annual report to holders

Mar 29

Proxy statement PRE 14A

Proxy statement

Feb 20

Current report 8-K

Financial results, Director or officer change, or executive pay

Feb 20

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $26.98M ▲ 86.5% Net loss $180.66M Diluted EPS -$5.08

Dec 14

Current report 8-K

Other events

Nov 2

Current report 8-K

Financial results

Nov 2

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $5.35M ▲ 76.1% Net loss $49.9M Diluted EPS -$1.26

Sep 11

Current report 8-K

Other events

Aug 3

Current report 8-K

Financial results

Aug 3

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $11.4M ▲ 160.3% Net loss $42.6M Diluted EPS -$1.41

Jul 13

Current report 8-K Events of Jul 12

Entered into a material agreement, Financial results, Other events

Jun 23

Current report 8-K Events of Jun 22

Director or officer change, or executive pay

Jun 14

Current report 8-K Events of Jun 13

Shareholder vote results

May 26

Current report 8-K

Other events

May 26

Registration statement S-3ASR

Registration statement

May 10

Current report 8-K Events of May 4

Entered into a material agreement

May 4

Current report 8-K

Financial results

May 4

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $4.9M ▲ 26.8% Net loss $39.06M Diluted EPS -$1.30

Apr 28

Proxy statement DEF 14A Meeting Jun 13, 2023

Proxy statement

Apr 28

Annual report to holders ARS

Annual report to holders

Apr 13

Proxy statement PRE 14A Meeting Jun 13, 2023

Proxy statement

Apr 3

Current report 8-K Events of Mar 31

Other events

Mar 28

Current report 8-K Events of Mar 27

Entered into a material agreement

Feb 28

Current report 8-K

Financial results

Feb 28

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $14.46M ▲ 23.6% Net loss $112.72M Diluted EPS -$3.80

Feb 14

Current report 8-K

Other events

Jan 23

Current report 8-K Events of Jan 17

Director or officer change, or executive pay

Nov 8

Current report 8-K

Other events

Nov 3

Current report 8-K

Financial results

Nov 3

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Revenue $3.04M ▼ 29.8% Net loss $28.35M Diluted EPS -$0.96

Sep 7

Current report 8-K

Other events

Aug 4

Current report 8-K

Financial results, Other events

Aug 4

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Revenue $4.38M ▲ 145.3% Net loss $26.83M Diluted EPS -$0.90

Jul 15

Current report 8-K

Entered into a material agreement

Jul 12

Current report 8-K

Other events

Jun 27

Current report 8-K

Shareholder vote results

May 5

Current report 8-K

Financial results, Other events

May 5

Quarterly report 10-Q FY2022 Q1, ended Mar 31

Quarterly report for FY2022 Q1

Revenue $3.86M ▲ 113.5% Net loss $27.56M Diluted EPS -$0.93

Apr 29

Proxy statement DEF 14A Meeting Jun 27, 2022

Proxy statement

Apr 15

Proxy statement PRE 14A Meeting Jun 27, 2022

Proxy statement

Apr 12

Current report 8-K Events of Apr 11

Other events

Mar 1

Current report 8-K

Financial results

Mar 1

Annual report 10-K FY2021, ended Dec 31

Annual report for FY2021

Revenue $11.7M ▲ 12.6% Net loss $66.82M Diluted EPS -$2.67

Jan 5

Current report 8-K Events of Jan 3

Director or officer change, or executive pay, Regulation FD disclosure, Other events

Nov 8

Current report 8-K

Regulation FD disclosure

Nov 4

Current report 8-K

Financial results, Other events

Nov 4

Quarterly report 10-Q FY2021 Q3, ended Sep 30

Quarterly report for FY2021 Q3

Revenue $4.33M ▲ 12.8% Net loss $14.68M Diluted EPS -$0.59

Oct 26

Current report 8-K

Other events

Oct 14

Current report 8-K Events of Oct 12

Entered into a material agreement, Financial results